Coagulation modifiers targeting SARS-CoV-2 main protease Mpro for COVID-19 treatment: an in silico approach
Mem. Inst. Oswaldo Cruz
;
115: e200179, 2020. graf
Article
in English
| LILACS, SES-SP
| ID: biblio-1135266
ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection depends on viral polyprotein processing, catalysed by the main proteinase (Mpro). The solution of the SARS-CoV-2 Mpro structure allowed the investigation of potential inhibitors. This work aims to provide first evidences of the applicability of commercially approved drugs to treat coronavirus disease-19 (COVID-19). We screened 4,334 compounds to found potential inhibitors of SARS-CoV-2 replication using an in silico approach. Our results evidenced the potential use of coagulation modifiers in COVID-19 treatment due to the structural similarity of SARS-CoV-2 Mpro and human coagulation factors thrombin and Factor Xa. Further in vitro and in vivo analysis are needed to corroborate these results.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Protease Inhibitors
/
Viral Nonstructural Proteins
/
Betacoronavirus
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
Mem. Inst. Oswaldo Cruz
Year:
2020
Type:
Article
Institution/Affiliation country:
Fundação Oswaldo Cruz-Fiocruz/BR
Similar
MEDLINE
...
LILACS
LIS